Pure Global
NCT06229990

Protocol Based-furosemide Stress Test Versus Standard Care to Evaluate Renal Recovery During Continuous Renal Replacement Therapy

Protocol Based-furosemide Stress Test Versus Standard Care to Evaluate Renal Recovery During Continuous Renal Replacement Therapy: A Randomized Controlled Trial
Chiang Mai University·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Kidney Injury
Drug/Device/Intervention
Furosemide Injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chiang Mai University
Location
Chiang Mai, Thailand
Timeline & enrollment
Phase
Phase 4
Start date
Jan 01, 2024
End date
Jun 07, 2024
Enrollment
40 participants
Primary outcome

% of patients with Renal recovery

Summary

Currently, continuous renal replacement therapy (CRRT) is the main modality for renal support
 in critically ill patients with hemodynamic instability. Most studies have investigated the
 timing of RRT initiation. However, prolonged CRRT demonstrated the association of many
 unexpected events, such as catheter-related complications, catheter-related blood stream
 infection, hypotension, hypothermia, tachycardia, and atrial fibrillation. Up to now, there
 is a lack of evidence regarding the timing of withholding CRRT. The furosemide stress test
 (FST) is a tool that is easy to use and has more availability. The investigators aimed to
 apply FST to evaluate renal recovery compared with standard treatment in critically ill
 patients undergoing CRRT.

ICD-10 classifications
Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06229990
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06229990 through Pure Global AI's free database. This Phase 4 trial is sponsored by Chiang Mai University and is currently Recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.